Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Location: United States, Illinois, Chicago
Employees: 51-200
Founded date: 2011
Investors 3
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Montrose C... | montroseca... |
| - | Abingworth... | abingworth... |
Mentions in press and media 6
| Date | Title | Description |
| 11.12.2021 | Exicure, Inc. Announces Prepayment of $10.0 Million of its Outstanding Loans Under its Senior Secured Term Loan Debt Facility | Exicure, Inc. announced a prepayment of $10.0 million of its outstanding loans under its senior secured term loan debt facility with MidCap Financial Trust, as agent, and Silicon Valley Bank (SVB), leaving a remaining outstanding balance of... |
| 01.12.2017 | Chicago Startups Raised $184M in Venture Funding in November | Chicago-area tech and startup companies brought in a significant amount of money in November, making for what should be a strong close to the year. Collectively, area tech and startup companies raised at least $184 million, based on public ... |
| 06.11.2017 | Exicure raises $11.2M in cash as psoriasis, I-O assets near clinical trials | Exicure has pulled in more money to advance its pipeline of oligonucleotides. The latest raise sees Exicure branch out beyond the tech investors that bankrolled its atypical rise to secure cash for its move deeper into the clinic. China’s L... |
| 14.10.2017 | A biotech backed by Bill Gates is developing therapies that could treat everything from skin diseases to cancer | David Giljohann Exicure CEO David Giljohann A Chicago-based biotech that's backed by Bill Gates wants to build treatments that can silence genes to treat diseases like cancer. Advertisement In September, Exicure, led by 36-year-old David Gi... |
| 12.12.2016 | Purdue and Exicure sign deal worth up to $790M | For that investment, Purdue gets an option and licensing agreement for an investigational psoriasis drug and three other molecules based on the same novel nucleic acid platform. Perhaps more importantly, the villainized owner of the widely ... |
| - | Purdue and Exicure sign deal worth up to $790M | A startup dream has been realized, while an old pharma company tries to turn a new leaf. On Monday, 60-year-old Purdue Pharma announced a strategic partnership with Exicure, a 2009 startup that could pull as much as $790 million and royalti... |